Carmignac Gestion Purchases Shares of 448,606 Organon & Co. $OGN

Carmignac Gestion acquired a new stake in Organon & Co. (NYSE:OGN) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 448,606 shares of the company’s stock, valued at approximately $6,074,000. Carmignac Gestion owned approximately 0.17% of Organon & Co. as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Allied Private Wealth LLC bought a new stake in Organon & Co. in the second quarter valued at about $33,000. Eurizon Capital SGR S.p.A. acquired a new stake in Organon & Co. during the fourth quarter valued at approximately $44,000. Kestra Advisory Services LLC bought a new stake in shares of Organon & Co. in the 4th quarter valued at approximately $47,000. WNY Asset Management LLC bought a new stake in shares of Organon & Co. in the 1st quarter valued at approximately $64,000. Finally, Empowered Funds LLC acquired a new position in shares of Organon & Co. in the 4th quarter worth approximately $74,000. 77.43% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Organon & Co. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd. Five analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus price target of $11.40.

Organon & Co. Price Performance

NYSE:OGN traded down $0.01 on Tuesday, reaching $13.77. The stock had a trading volume of 1,629,810 shares, compared to its average volume of 5,635,393. The company has a market capitalization of $3.61 billion, a P/E ratio of 17.88, a price-to-earnings-growth ratio of 1.28 and a beta of 1.52. Organon & Co. has a 1-year low of $5.69 and a 1-year high of $13.78. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43. The stock has a fifty day moving average price of $13.62 and a 200-day moving average price of $11.38.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $0.02 dividend. The ex-dividend date is Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.’s payout ratio is 10.39%.

Organon & Co. Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.